<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0&amp;utm_source=Chrome&amp;ff=20240104193946&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0&amp;utm_source=Chrome&amp;ff=20240104193946&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Fri, 05 Jan 2024 00:39:47 +0000</lastbuilddate>
<pubDate>Thu, 04 Jan 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Legumain Regulates Regulatory T Cells in Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38175912/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):30-32. doi: 10.1161/CIRCRESAHA.123.324010. Epub 2024 Jan 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38175912/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38175912</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324010>10.1161/CIRCRESAHA.123.324010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38175912</guid>
<pubDate>Thu, 04 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Matthew R Alexander</dc:creator>
<dc:creator>David G Harrison</dc:creator>
<dc:date>2024-01-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Legumain Regulates Regulatory T Cells in Hypertension</dc:title>
<dc:identifier>pmid:38175912</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324010</dc:identifier>
</item>
<item>
<title>Shedding Light on the Roles of Ceramide in Human Microvascular Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38175911/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):97-99. doi: 10.1161/CIRCRESAHA.123.323868. Epub 2024 Jan 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38175911/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38175911</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323868>10.1161/CIRCRESAHA.123.323868</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38175911</guid>
<pubDate>Thu, 04 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Charles D Searles</dc:creator>
<dc:date>2024-01-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Shedding Light on the Roles of Ceramide in Human Microvascular Function</dc:title>
<dc:identifier>pmid:38175911</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323868</dc:identifier>
</item>
<item>
<title>Exploring the Connection Between Relaxed Myosin States and the Anrep Effect</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38175910/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>The Anrep effect is an adaptive response that increases left ventricular contractility following an acute rise in afterload. Although the mechanistic origin remains undefined, recent findings suggest a two-phase activation of resting myosin for contraction, involving strain-sensitive and posttranslational phases. We propose that this mobilization represents a transition among the relaxed states of myosin-specifically, from the super-relaxed (SRX) to the disordered-relaxed (DRX)-with DRX myosin...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):117-134. doi: 10.1161/CIRCRESAHA.123.323173. Epub 2024 Jan 4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The Anrep effect is an adaptive response that increases left ventricular contractility following an acute rise in afterload. Although the mechanistic origin remains undefined, recent findings suggest a two-phase activation of resting myosin for contraction, involving strain-sensitive and posttranslational phases. We propose that this mobilization represents a transition among the relaxed states of myosin-specifically, from the super-relaxed (SRX) to the disordered-relaxed (DRX)-with DRX myosin ready to participate in force generation. This hypothesis offers a unified explanation that connects myosin's SRX-DRX equilibrium and the Anrep effect as parts of a singular phenomenon. We underscore the significance of this equilibrium in modulating contractility, primarily studied in the context of hypertrophic cardiomyopathy, the most common inherited cardiomyopathy associated with diastolic dysfunction, hypercontractility, and left ventricular hypertrophy. As we posit that the cellular basis of the Anrep effect relies on a two-phased transition of myosin from the SRX to the contraction-ready DRX configuration, any dysregulation in this equilibrium may result in the pathological manifestation of the Anrep phenomenon. For instance, in hypertrophic cardiomyopathy, hypercontractility is linked to a considerable shift of myosin to the DRX state, implying a persistent activation of the Anrep effect. These valuable insights call for additional research to uncover a clinical Anrep fingerprint in pathological states. Here, we demonstrate through noninvasive echocardiographic pressure-volume measurements that this fingerprint is evident in 12 patients with hypertrophic obstructive cardiomyopathy before septal myocardial ablation. This unique signature is characterized by enhanced contractility, indicated by a leftward shift and steepening of the end-systolic pressure-volume relationship, and a prolonged systolic ejection time adjusted for heart rate, which reverses post-procedure. The clinical application of this concept has potential implications beyond hypertrophic cardiomyopathy, extending to other genetic cardiomyopathies and even noncongenital heart diseases with complex etiologies across a broad spectrum of left ventricular ejection fractions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38175910/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38175910</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323173>10.1161/CIRCRESAHA.123.323173</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38175910</guid>
<pubDate>Thu, 04 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Vasco Sequeira</dc:creator>
<dc:creator>Christoph Maack</dc:creator>
<dc:creator>Gert-Hinrich Reil</dc:creator>
<dc:creator>Jan-Christian Reil</dc:creator>
<dc:date>2024-01-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Exploring the Connection Between Relaxed Myosin States and the Anrep Effect</dc:title>
<dc:identifier>pmid:38175910</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323173</dc:identifier>
</item>
<item>
<title>Editors and Editorial Board</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38175909/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):1. doi: 10.1161/RES.0000000000000652. Epub 2024 Jan 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38175909/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38175909</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000652>10.1161/RES.0000000000000652</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38175909</guid>
<pubDate>Thu, 04 Jan 2024 06:00:00 -0500</pubDate>
<dc:date>2024-01-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Editors and Editorial Board</dc:title>
<dc:identifier>pmid:38175909</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000652</dc:identifier>
</item>
<item>
<title>In This Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38175908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):2. doi: 10.1161/RES.0000000000000650. Epub 2024 Jan 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38175908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38175908</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000650>10.1161/RES.0000000000000650</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38175908</guid>
<pubDate>Thu, 04 Jan 2024 06:00:00 -0500</pubDate>
<dc:date>2024-01-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In This Issue</dc:title>
<dc:identifier>pmid:38175908</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000650</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38175907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):3-5. doi: 10.1161/RES.0000000000000651. Epub 2024 Jan 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38175907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38175907</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000651>10.1161/RES.0000000000000651</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38175907</guid>
<pubDate>Thu, 04 Jan 2024 06:00:00 -0500</pubDate>
<dc:date>2024-01-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38175907</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000651</dc:identifier>
</item>
<item>
<title>Circulation Research and 70 Years of Basic Science: Examining the Past and Looking Forward to the Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38175906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):6-8. doi: 10.1161/CIRCRESAHA.123.323177. Epub 2024 Jan 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38175906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38175906</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323177>10.1161/CIRCRESAHA.123.323177</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38175906</guid>
<pubDate>Thu, 04 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Jane E Freedman</dc:creator>
<dc:date>2024-01-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Circulation Research and 70 Years of Basic Science: Examining the Past and Looking Forward to the Future</dc:title>
<dc:identifier>pmid:38175906</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323177</dc:identifier>
</item>
<item>
<title>Directional Endothelial Communication by Polarized Extracellular Vesicle Release</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38174557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>CONCLUSIONS: Demonstrating that ECs are capable of polarized EV cargo loading and directional EV secretion reveals a novel paradigm for endothelial communication, which may ultimately enhance the design of endothelial-based therapeutics for cardiovascular diseases such as atherosclerosis where ECs are persistently activated.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 4. doi: 10.1161/CIRCRESAHA.123.322993. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Extracellular vesicles (EVs) contain bioactive cargo including miRNAs and proteins that are released by cells during cell-cell communication. Endothelial cells (ECs) form the innermost lining of all blood vessels, interfacing with cells in the circulation and vascular wall. It is unknown whether ECs release EVs capable of governing recipient cells within these 2 separate compartments. Given their boundary location, we propose ECs use bidirectional release of distinct EV cargo in quiescent (healthy) and activated (atheroprone) states to communicate with cells within the circulation and blood vessel wall.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: EVs were isolated from primary human aortic ECs (plate and transwell grown; ±IL [interleukin]-1β activation), quantified, visualized, and analyzed by miRNA transcriptomics and proteomics. Apical and basolateral EC-EV release was determined by miRNA transfer, total internal reflectance, and electron microscopy. Vascular reprogramming (RNA sequencing) and functional assays were performed on primary human monocytes or smooth muscle cells±EC-EVs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Activated ECs increased EV release, with miRNA and protein cargo related to atherosclerosis. EV-treated monocytes and smooth muscle cells revealed activated EC-EV altered pathways that were proinflammatory and atherogenic. ECs released more EVs apically, which increased with activation. Apical and basolateral EV cargo contained distinct transcriptomes and proteomes that were altered by EC activation. Notably, activated basolateral EC-EVs displayed greater changes in the EV secretome, with pathways specific to atherosclerosis. In silico analysis determined compartment-specific cargo released by the apical and basolateral surfaces of ECs can reprogram monocytes and smooth muscle cells, respectively, with functional assays and in vivo imaging supporting this concept.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Demonstrating that ECs are capable of polarized EV cargo loading and directional EV secretion reveals a novel paradigm for endothelial communication, which may ultimately enhance the design of endothelial-based therapeutics for cardiovascular diseases such as atherosclerosis where ECs are persistently activated.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38174557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38174557</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322993>10.1161/CIRCRESAHA.123.322993</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38174557</guid>
<pubDate>Thu, 04 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Sneha Raju</dc:creator>
<dc:creator>Steven R Botts</dc:creator>
<dc:creator>Mark C Blaser</dc:creator>
<dc:creator>Majed Abdul-Samad</dc:creator>
<dc:creator>Kamalben Prajapati</dc:creator>
<dc:creator>Negar Khosraviani</dc:creator>
<dc:creator>Tse Wing Winnie Ho</dc:creator>
<dc:creator>Leandro C D Breda</dc:creator>
<dc:creator>Crizza Ching</dc:creator>
<dc:creator>Natalie J Galant</dc:creator>
<dc:creator>Lindsey Fiddes</dc:creator>
<dc:creator>Ruilin Wu</dc:creator>
<dc:creator>Cassandra L Clift</dc:creator>
<dc:creator>Tan Pham</dc:creator>
<dc:creator>Warren L Lee</dc:creator>
<dc:creator>Sasha A Singh</dc:creator>
<dc:creator>Elena Aikawa</dc:creator>
<dc:creator>Jason E Fish</dc:creator>
<dc:creator>Kathryn L Howe</dc:creator>
<dc:date>2024-01-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Directional Endothelial Communication by Polarized Extracellular Vesicle Release</dc:title>
<dc:identifier>pmid:38174557</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322993</dc:identifier>
</item>
<item>
<title>Improving medication adherence in cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38172243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>Non-adherence to medication is a global health problem with far-reaching individual-level and population-level consequences but remains unappreciated and under-addressed in the clinical setting. With increasing comorbidity and polypharmacy as well as an ageing population, cardiovascular disease and medication non-adherence are likely to become increasingly prevalent. Multiple methods for detecting non-adherence exist but are imperfect, and, despite emerging technology, a gold standard remains...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 3. doi: 10.1038/s41569-023-00972-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Non-adherence to medication is a global health problem with far-reaching individual-level and population-level consequences but remains unappreciated and under-addressed in the clinical setting. With increasing comorbidity and polypharmacy as well as an ageing population, cardiovascular disease and medication non-adherence are likely to become increasingly prevalent. Multiple methods for detecting non-adherence exist but are imperfect, and, despite emerging technology, a gold standard remains elusive. Non-adherence to medication is dynamic and often has multiple causes, particularly in the context of cardiovascular disease, which tends to require lifelong medication to control symptoms and risk factors in order to prevent disease progression. In this Review, we identify the causes of medication non-adherence and summarize interventions that have been proven in randomized clinical trials to be effective in improving adherence. Practical solutions and areas for future research are also proposed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38172243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38172243</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00972-1>10.1038/s41569-023-00972-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38172243</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam J Nelson</dc:creator>
<dc:creator>Neha J Pagidipati</dc:creator>
<dc:creator>Hayden B Bosworth</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Improving medication adherence in cardiovascular disease</dc:title>
<dc:identifier>pmid:38172243</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00972-1</dc:identifier>
</item>
<item>
<title>Immune and inflammatory mechanisms in hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38172242/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>Hypertension is a global health problem, with >;1.3 billion individuals with high blood pressure worldwide. In this Review, we present an inflammatory paradigm for hypertension, emphasizing the crucial roles of immune cells, cytokines and chemokines in disease initiation and progression. T cells, monocytes, macrophages, dendritic cells, B cells and natural killer cells are all implicated in hypertension. Neoantigens, the NLRP3 inflammasome and increased sympathetic outflow, as well as cytokines...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 3. doi: 10.1038/s41569-023-00964-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hypertension is a global health problem, with >;1.3 billion individuals with high blood pressure worldwide. In this Review, we present an inflammatory paradigm for hypertension, emphasizing the crucial roles of immune cells, cytokines and chemokines in disease initiation and progression. T cells, monocytes, macrophages, dendritic cells, B cells and natural killer cells are all implicated in hypertension. Neoantigens, the NLRP3 inflammasome and increased sympathetic outflow, as well as cytokines (including IL-6, IL-7, IL-15, IL-18 and IL-21) and a high-salt environment, can contribute to immune activation in hypertension. The activated immune cells migrate to target organs such as arteries (especially the perivascular fat and adventitia), kidneys, the heart and the brain, where they release effector cytokines that elevate blood pressure and cause vascular remodelling, renal damage, cardiac hypertrophy, cognitive impairment and dementia. IL-17 secreted by CD4<sup>+</sup> T helper 17 cells and γδ T cells, and interferon-γ and tumour necrosis factor secreted by immunosenescent CD8<sup>+</sup> T cells, exert crucial effector roles in hypertension, whereas IL-10 and regulatory T cells are protective. Effector mediators impair nitric oxide bioavailability, leading to endothelial dysfunction and increased vascular contractility. Inflammatory effector mediators also alter renal sodium and water balance and promote renal fibrosis. These mechanisms link hypertension with obesity, autoimmunity, periodontitis and COVID-19. A comprehensive understanding of the immune and inflammatory mechanisms of hypertension is crucial for safely and effectively translating the findings to clinical practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38172242/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38172242</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00964-1>10.1038/s41569-023-00964-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38172242</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Tomasz J Guzik</dc:creator>
<dc:creator>Ryszard Nosalski</dc:creator>
<dc:creator>Pasquale Maffia</dc:creator>
<dc:creator>Grant R Drummond</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Immune and inflammatory mechanisms in hypertension</dc:title>
<dc:identifier>pmid:38172242</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00964-1</dc:identifier>
</item>
<item>
<title>Clinically Significant Differences Between P2Y&lt;sub>;12&lt;/sub>; Inhibitor Monotherapy and Aspirin Monotherapy Have Yet to Be Demonstrated</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171716/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):e9-e10. doi: 10.1016/j.jacc.2023.09.833.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171716/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171716</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.833>10.1016/j.jacc.2023.09.833</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171716</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Eric R Bates</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinically Significant Differences Between P2Y&lt;sub>;12&lt;/sub>; Inhibitor Monotherapy and Aspirin Monotherapy Have Yet to Be Demonstrated</dc:title>
<dc:identifier>pmid:38171716</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.833</dc:identifier>
</item>
<item>
<title>Aspirin vs P2Y&lt;sub>;12&lt;/sub>; Inhibitors: A Few Questions Unanswered</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171715/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):e7. doi: 10.1016/j.jacc.2023.09.832.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171715/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171715</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.832>10.1016/j.jacc.2023.09.832</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171715</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Mostafa Reda Mostafa</dc:creator>
<dc:creator>Claudine Abdou</dc:creator>
<dc:creator>Kirolos Barssoum</dc:creator>
<dc:creator>Hani Jneid</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aspirin vs P2Y&lt;sub>;12&lt;/sub>; Inhibitors: A Few Questions Unanswered</dc:title>
<dc:identifier>pmid:38171715</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.832</dc:identifier>
</item>
<item>
<title>Reply: Unconvinced by Data or Resistance to Change?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):e11-e12. doi: 10.1016/j.jacc.2023.10.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171714</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.027>10.1016/j.jacc.2023.10.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171714</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Felice Gragnano</dc:creator>
<dc:creator>Paolo Calabrò</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>PANTHER Collaboration</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Unconvinced by Data or Resistance to Change?</dc:title>
<dc:identifier>pmid:38171714</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.027</dc:identifier>
</item>
<item>
<title>Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>Electrophysiological and interventional procedures have been increasingly used to reduce morbidity and mortality in patients experiencing cardiovascular diseases. Although antithrombotic therapies are critical to reduce the risk of stroke or other thromboembolic events, they can nonetheless increase the bleeding hazard. This is even more true in an aging population undergoing cardiac procedures in which the combination of oral anticoagulants and antiplatelet therapies would further increase the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):82-108. doi: 10.1016/j.jacc.2023.09.831.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Electrophysiological and interventional procedures have been increasingly used to reduce morbidity and mortality in patients experiencing cardiovascular diseases. Although antithrombotic therapies are critical to reduce the risk of stroke or other thromboembolic events, they can nonetheless increase the bleeding hazard. This is even more true in an aging population undergoing cardiac procedures in which the combination of oral anticoagulants and antiplatelet therapies would further increase the hemorrhagic risk. Hence, the timing, dose, and combination of antithrombotic therapies should be carefully chosen in each case. However, the maze of society guidelines and consensus documents published so far have progressively led to a hazier scenario in this setting. Aim of this review is to provide-in a single document-a quick, evidenced-based practical summary of the antithrombotic approaches used in different cardiac electrophysiology and interventional procedures to guide the busy clinician and the cardiac proceduralist in their everyday practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171713</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.831>10.1016/j.jacc.2023.09.831</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171713</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Luigi Di Biase</dc:creator>
<dc:creator>Dhanunjaya J Lakkireddy</dc:creator>
<dc:creator>Jacopo Marazzato</dc:creator>
<dc:creator>Alejandro Velasco</dc:creator>
<dc:creator>Juan Carlos Diaz</dc:creator>
<dc:creator>Rachita Navara</dc:creator>
<dc:creator>Jonathan Chrispin</dc:creator>
<dc:creator>Bharath Rajagopalan</dc:creator>
<dc:creator>Andrea Natale</dc:creator>
<dc:creator>Sanghamitra Mohanty</dc:creator>
<dc:creator>Xiaodong Zhang</dc:creator>
<dc:creator>Domenico Della Rocca</dc:creator>
<dc:creator>Aarti Dalal</dc:creator>
<dc:creator>Ki Park</dc:creator>
<dc:creator>Jose Wiley</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>Jim W Cheung</dc:creator>
<dc:creator>George Dangas</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Jorge Romero</dc:creator>
<dc:creator>ACC Electrophysiology and Interventional Councils</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38171713</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.831</dc:identifier>
</item>
<item>
<title>Novel Techniques in Imaging Congenital Heart Disease: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171712/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>Recent years have witnessed exponential growth in cardiac imaging technologies, allowing better visualization of complex cardiac anatomy and improved assessment of physiology. These advances have become increasingly important as more complex surgical and catheter-based procedures are evolving to address the needs of a growing congenital heart disease population. This state-of-the-art review presents advances in echocardiography, cardiac magnetic resonance, cardiac computed tomography, invasive...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):63-81. doi: 10.1016/j.jacc.2023.10.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent years have witnessed exponential growth in cardiac imaging technologies, allowing better visualization of complex cardiac anatomy and improved assessment of physiology. These advances have become increasingly important as more complex surgical and catheter-based procedures are evolving to address the needs of a growing congenital heart disease population. This state-of-the-art review presents advances in echocardiography, cardiac magnetic resonance, cardiac computed tomography, invasive angiography, 3-dimensional modeling, and digital twin technology. The paper also highlights the integration of artificial intelligence with imaging technology. While some techniques are in their infancy and need further refinement, others have found their way into clinical workflow at well-resourced centers. Studies to evaluate the clinical value and cost-effectiveness of these techniques are needed. For techniques that enhance the value of care for congenital heart disease patients, resources will need to be allocated for education and training to promote widespread implementation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171712/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171712</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.025>10.1016/j.jacc.2023.10.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171712</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Ritu Sachdeva</dc:creator>
<dc:creator>Aimee K Armstrong</dc:creator>
<dc:creator>Rima Arnaout</dc:creator>
<dc:creator>Lars Grosse-Wortmann</dc:creator>
<dc:creator>B Kelly Han</dc:creator>
<dc:creator>Luc Mertens</dc:creator>
<dc:creator>Ryan A Moore</dc:creator>
<dc:creator>Laura J Olivieri</dc:creator>
<dc:creator>Anitha Parthiban</dc:creator>
<dc:creator>Andrew J Powell</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Novel Techniques in Imaging Congenital Heart Disease: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:38171712</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.025</dc:identifier>
</item>
<item>
<title>Inhalable Therapies for the Heart: Take the "Lung" Way Home?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171711/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):60-62. doi: 10.1016/j.jacc.2023.10.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171711/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171711</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.028>10.1016/j.jacc.2023.10.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171711</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Jean-Sébastien Hulot</dc:creator>
<dc:creator>Christian Kupatt</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Inhalable Therapies for the Heart: Take the "Lung" Way Home?</dc:title>
<dc:identifier>pmid:38171711</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.028</dc:identifier>
</item>
<item>
<title>Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171710/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>CONCLUSIONS: The overall tolerability of LungToHeartNIM along with the beneficial effects of the LTCC modulator point toward a game-changing treatment for HFrEF patients, also demonstrating the effective delivery of a therapeutic peptide to the diseased heart.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):47-59. doi: 10.1016/j.jacc.2023.10.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The lack of disease-modifying drugs is one of the major unmet needs in patients with heart failure (HF). Peptides are highly selective molecules with the potential to act directly on cardiomyocytes. However, a strategy for effective delivery of therapeutics to the heart is lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this study, the authors sought to assess tolerability and efficacy of an inhalable lung-to-heart nano-in-micro technology (LungToHeartNIM) for cardiac-specific targeting of a mimetic peptide (MP), a first-in-class for modulating impaired L-type calcium channel (LTCC) trafficking, in a clinically relevant porcine model of HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Heart failure with reduced ejection fraction (HFrEF) was induced in Göttingen minipigs by means of tachypacing over 6 weeks. In a setting of overt HFrEF (left ventricular ejection fraction [LVEF] 30% ± 8%), animals were randomized and treatment was started after 4 weeks of tachypacing. HFrEF animals inhaled either a dry powder composed of mannitol-based microparticles embedding biocompatible MP-loaded calcium phosphate nanoparticles (dpCaP-MP) or the LungToHeartNIM only (dpCaP without MP). Efficacy was evaluated with the use of echocardiography, invasive hemodynamics, and biomarker assessment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: DpCaP-MP inhalation restored systolic function, as shown by an absolute LVEF increase over the treatment period of 17% ± 6%, while reversing cardiac remodeling and reducing pulmonary congestion. The effect was recapitulated ex vivo in cardiac myofibrils from treated HF animals. The treatment was well tolerated, and no adverse events occurred.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The overall tolerability of LungToHeartNIM along with the beneficial effects of the LTCC modulator point toward a game-changing treatment for HFrEF patients, also demonstrating the effective delivery of a therapeutic peptide to the diseased heart.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171710/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171710</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.029>10.1016/j.jacc.2023.10.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171710</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Alessio Alogna</dc:creator>
<dc:creator>Leonhard Berboth</dc:creator>
<dc:creator>Alessandro Faragli</dc:creator>
<dc:creator>Jens Ötvös</dc:creator>
<dc:creator>Francesco Paolo Lo Muzio</dc:creator>
<dc:creator>Vittoria di Mauro</dc:creator>
<dc:creator>Jessica Modica</dc:creator>
<dc:creator>Eride Quarta</dc:creator>
<dc:creator>Lukas Semmler</dc:creator>
<dc:creator>Peter Maximilian Deißler</dc:creator>
<dc:creator>Yannic Wanja Berger</dc:creator>
<dc:creator>Khai Liem Tran</dc:creator>
<dc:creator>Beatrice de Marchi</dc:creator>
<dc:creator>Gianluigi Longinotti-Buitoni</dc:creator>
<dc:creator>Lorenzo Degli Esposti</dc:creator>
<dc:creator>Etienne Guillot</dc:creator>
<dc:creator>Didier Bazile</dc:creator>
<dc:creator>Michele Iafisco</dc:creator>
<dc:creator>Alessandro Dotti</dc:creator>
<dc:creator>Marie-Louise Bang</dc:creator>
<dc:creator>Claudio de Luca</dc:creator>
<dc:creator>Christina Brandenberger</dc:creator>
<dc:creator>Louise Benazzi</dc:creator>
<dc:creator>Dario di Silvestre</dc:creator>
<dc:creator>Antonella de Palma</dc:creator>
<dc:creator>Uwe Primeßnig</dc:creator>
<dc:creator>Felix Hohendanner</dc:creator>
<dc:creator>Simone Perna</dc:creator>
<dc:creator>Francesca Buttini</dc:creator>
<dc:creator>Paolo Colombo</dc:creator>
<dc:creator>Christian Mühlfeld</dc:creator>
<dc:creator>Paul Steendijk</dc:creator>
<dc:creator>Pierluigi Mauri</dc:creator>
<dc:creator>Carsten Tschöpe</dc:creator>
<dc:creator>Barry Borlaug</dc:creator>
<dc:creator>Burkert M Pieske</dc:creator>
<dc:creator>Philipp Attanasio</dc:creator>
<dc:creator>Heiner Post</dc:creator>
<dc:creator>Frank R Heinzel</dc:creator>
<dc:creator>Daniele Catalucci</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure</dc:title>
<dc:identifier>pmid:38171710</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.029</dc:identifier>
</item>
<item>
<title>High-Risk Acute Pulmonary Embolism: Where Do We Go From Here?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171709/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):44-46. doi: 10.1016/j.jacc.2023.11.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171709/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171709</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.001>10.1016/j.jacc.2023.11.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171709</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Behnam N Tehrani</dc:creator>
<dc:creator>Wayne B Batchelor</dc:creator>
<dc:creator>David Spinosa</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>High-Risk Acute Pulmonary Embolism: Where Do We Go From Here?</dc:title>
<dc:identifier>pmid:38171709</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.001</dc:identifier>
</item>
<item>
<title>Contemporary Management and Outcomes of Patients With High-Risk Pulmonary Embolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171708/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>CONCLUSIONS: In the largest analysis of high-risk PE patients to date, mortality rates were high with the worst outcomes among patients with hemodynamic collapse.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):35-43. doi: 10.1016/j.jacc.2023.10.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Contemporary care patterns/outcomes in high-risk pulmonary embolism (PE) patients are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to characterize the management of high-risk PE patients and identify factors associated with poor outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A retrospective analysis of the PERT (Pulmonary Embolism Response Team) Consortium Registry was performed. Patients presenting with intermediate-risk PE, high-risk PE, and catastrophic PE (those with hemodynamic collapse) were identified. Patient characteristics were compared with chi-square testing for categorical covariates and Student's t-test for continuous covariates. Multivariable logistic regression was used to assess associations between clinical characteristics and outcomes in the high-risk population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 5,790 registry patients, 2,976 presented with intermediate-risk PE and 1,442 with high-risk PE. High-risk PE patients were more frequently treated with advanced therapies than intermediate-risk PE patients (41.9% vs 30.2%; P &lt; 0.001). In-hospital mortality (20.6% vs 3.7%; P &lt; 0.001) and major bleeding (10.5% vs. 3.5%; P &lt; 0.001) were more common in high-risk PE. Multivariable regression analysis demonstrated vasopressor use (OR: 4.56; 95% CI: 3.27-6.38; P &lt; 0.01), extracorporeal membrane oxygenation use (OR: 2.86; 95% CI: 1.12-7.30; P = 0.03), identified clot-in-transit (OR: 2.26; 95% CI: 1.13-4.52; P = 0.02), and malignancy (OR: = 1.70; 95% CI: 1.13-2.56; P = 0.01) as factors associated with in-hospital mortality. Catastrophic PE patients (n = 197 [13.7% of high-risk PE patients]) had higher in-hospital mortality (42.1% vs 17.2%; P &lt; 0.001) than those presenting with noncatastrophic high-risk PE. Extracorporeal membrane oxygenation (13.3% vs. 4.8% P &lt; 0.001) and systemic thrombolysis (25% vs 11.3%; P &lt; 0.001) were used more commonly in catastrophic PE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the largest analysis of high-risk PE patients to date, mortality rates were high with the worst outcomes among patients with hemodynamic collapse.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171708/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171708</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.026>10.1016/j.jacc.2023.10.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171708</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Taisei Kobayashi</dc:creator>
<dc:creator>Steven Pugliese</dc:creator>
<dc:creator>Sanjum S Sethi</dc:creator>
<dc:creator>Sahil A Parikh</dc:creator>
<dc:creator>Joshua Goldberg</dc:creator>
<dc:creator>Fahad Alkhafan</dc:creator>
<dc:creator>Clara Vitarello</dc:creator>
<dc:creator>Kenneth Rosenfield</dc:creator>
<dc:creator>Robert Lookstein</dc:creator>
<dc:creator>Brent Keeling</dc:creator>
<dc:creator>Andrew Klein</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Lauren Glassmoyer</dc:creator>
<dc:creator>Sameer Khandhar</dc:creator>
<dc:creator>Eric Secemsky</dc:creator>
<dc:creator>Jay Giri</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Contemporary Management and Outcomes of Patients With High-Risk Pulmonary Embolism</dc:title>
<dc:identifier>pmid:38171708</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.026</dc:identifier>
</item>
<item>
<title>Clopidogrel for Long-Term Secondary Prevention After Coronary Artery Stenting</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):32-34. doi: 10.1016/j.jacc.2023.11.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171707</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.004>10.1016/j.jacc.2023.11.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171707</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Anne Bellemain-Appaix</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clopidogrel for Long-Term Secondary Prevention After Coronary Artery Stenting</dc:title>
<dc:identifier>pmid:38171707</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.004</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38171706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240104193946&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 2;83(1):290. doi: 10.1016/j.jacc.2023.11.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38171706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240104193946&v=2.18.0">38171706</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.011>10.1016/j.jacc.2023.11.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38171706</guid>
<pubDate>Wed, 03 Jan 2024 06:00:00 -0500</pubDate>
<dc:date>2024-01-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:38171706</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.011</dc:identifier>
</item>





























</channel>
</rss>